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Matrix metalloproteinases (MMPs) are proteolytic anchored into the membrane). The activity of the MMPs can be regulated either by modulation of pro-enzyme enzymes that can degrade extracellular matrix componproduction and/or activation, or by changes in the levels ents [1] . These enzymes are synthesized as latent proof inhibitors of MMPs such as a2-macroglobulin and enzymes, contain a zinc binding active site, and require tissue inhibitors of matrix metalloproteinases ( TIMPs) Ca2+ and proteolytic cleavage for activation. The MMP [2, 3] . An imbalance between these inhibitors and the family includes four different groups of enzymes: (I ) proteinases conceivably leads to matrix degradation collagenases (interstitial collagenase 1 or MMP-1, neu- [4, 5] . trophil-type collagenase 2 or MMP-8 and collagenase 3
The MMPs play an important role both in normal or MMP-13); (II ) gelatinases (gelatinase A or MMP-2 physiological processes and in pathological conditions and gelatinase B or MMP-9); (III ) stromelysins such as arthritis. In patients with rheumatoid arthritis (stromelysin-1 or MMP-3, stromelysin-2 or MMP-10);
(RA), the MMPs play a major role in the destruction (IV ) others (matrilysin, stromelysin-3, metalloelastase of cartilage and other components of connective tissue and membrane-type MMPs which are not secreted but in the joints. MMPs are released by synovial fibroblasts, chondrocytes, macrophages, neutrophils and endothelial cells in response to pro-inflammatory cytokines like
Of the MMP family, MMP-3 is thought to play a to the 1987 ACR criteria [25] , with joint symptoms existing for <1 yr at presentation and who had not prominent role in the pathogenesis of RA even though it is not the only key enzyme in matrix degradation in previously received disease-modifying anti-rheumatic drugs (DMARDs). These patients participated in a this disease [8] . MMP-3 is capable of degrading many components of matrix proteins in the synovial joint, prospective follow-up study at the department of rheumatology at the Groningen University Hospital. including proteoglycans, gelatins, laminin, fibronectin and collagens III, IV, IX, X [1, [9] [10] [11] . The enzyme has During follow-up, patients were treated with nonsteroidal anti-inflammatory drugs and DMARDs as been localized in the fibroblast-like synovial lining cell of rheumatoid synovium [12, 13] and in RA cartilages indicated clinically. Guidelines for the sequence of the different second-line drugs were as follows: hydroxy- [4, 5] . It is secreted as a latent pro-enzyme resulting in highly elevated MMP-3 levels in synovial fluid of RA chloroquine or sulphasalazine as first-choice therapy, followed in order by i.m. gold, -penicillamine, azathiopatients [14] [15] [16] . Although serum levels are (300-500 times) lower, there is a highly significant correlation prine or methotrexate. Low-dose corticosteroids could be administered as adjuvant therapy. with matched synovial fluid levels, indicating that serum MMP-3 is derived mainly from the inflamed synovium Out of this cohort, 48 consecutive RA patients without X-ray damage and a randomly chosen group of 30 RA [14, [16] [17] [18] [19] [20] . Levels of activated MMP-3 are also highly increased in synovial fluid [21] , but measurement of patients with X-ray damage due to RA at presentation were selected. In the group of 48 RA patients without activated MMP-3 in serum will be very difficult, if not impossible, because of the high serum levels of initial X-ray damage, 19 patients did not develop X-ray damage during the 2 yr of follow-up [RA-00 group; a2-macroglobulin, which encloses the activated proteinase completely [3] .
initially no X-ray damage (= 0) and after 2 yr no X-ray damage (= 0)]. The remaining 29 patients developed In RA serum, MMP-3 could be a specific marker of joint inflammation and destruction because it is almost X-ray damage (1 or more Sharp points) during the 2 yr of follow-up [RA-0X group; initially no X-ray damage exclusively produced locally, in the inflamed synovium. In that case, it could be used in the early identification (= 0), after 2 yr X-ray damage (= X )]. Clinical (number of painful joints, number of swollen of patients with aggressive destructive disease, which is important for therapeutic reasons [22] .
joints, Ritchie articular index) and laboratory (CRP) investigations were performed at monthly visits during Several other features, such as age, HLA-DR4, rheumatoid factor (RF ) and C-reactive protein (CRP) 2 yr. Radiographs of hands and feet were obtained at study production, also appear to be prognostic for the final outcome [23] . Although CRP is a good parameter for entry and every 6 months during 2 yr. Joint damage in the hands and feet was assessed by Sharp's method with prognostic purposes [24] and for monitoring treatment effects, it is an indicator of inflammation in general, some modifications, in particular inclusion of foot joints, as described by Van der Heijde [26 ] and Van der Heijde which may be influenced by other stimuli of the acutephase response; this in contrast with MMP-3 [17] .
et al. [27] . By this method, joint space narrowing and erosions are scored separately and combined in a total Previous studies of serum MMP-3 levels in RA concerned patients with a long disease duration [14, 16, 18, X-ray damage score. The radiographs were scored without knowledge of clinical and laboratory data in chrono -20] . Investigation in an early phase of the disease and, in particular, in a group of patients without initial logical order per patient by two observers (MvL and HAC ). The interobserver agreement was 0.90 and the radiological damage ( X-ray damage) has, to our knowledge, not been reported. intra-observer agreements were 0.96 and 0.99 for the two observers, respectively. The radiographic score in In the present study, we measured the levels of MMP-3 in sera from patients with early RA without X-ray the group of RA patients with initial X-ray damage (RA-XX ) was 5 or more at study entry. For analysis, damage at presentation and compared these with serum levels in RA patients with X-ray damage already at we used the variables at presentation ( T0) and after 6, 12 and 24 months. Of the group of 30 RA patients with presentation, osteoarthritis (OA) patients and healthy controls (CTRL). In the group of RA patients without X-ray damage at presentation (RA-XX ), only the variables at study entry were used. OA was diagnosed from initial X-ray damage, we analysed whether serum MMP-3 levels have a predictive value for the developclinical and radiological investigations using the ACR criteria for OA [28] [29] [30] . The CTRL were blood bank ment of X-ray damage. Furthermore, we investigated in this selected group of RA patients the relationship donors. between serum MMP-3 levels and CRP.
Measurement of MMP-3
Serum samples were obtained at 0, 6, 12 and 24 months. MMP-3 levels were determined with an MMP-3 ELISA Patients and methods developed in our laboratory. In short, 96-well plates Patients were pre-coated with the F(ab) 2 fragment of goat anti-mouse Ig, 1 mg/ml (Jackson Immunoresearch Labs, Seventy-eight patients with RA, 19 patients with OA and 46 CTRL were studied. The RA patients were West Grove, PA, USA). Next, a mouse monoclonal antibody against human MMP-3, clone 55-2-A4 (clone selected from a cohort of patients with RA, according 
Results
Peroxidase activity was determined using tetramethylbenzidine as substrate. MMP-3 levels were calculated in Characteristics of control subjects, OA and RA patients the linear range of the assay from a standard curve are summarized in Table 1 . (10-1500 ng/ml ) using an RA synovial fluid, which was All OA patients had OA of the hands according to standardized against the BIOTRAKB standard (see the ACR criteria. Nine out of 19 patients had also OA below). The intra-assay coefficient of variation (CV ) of the knees or hips. There was one male OA patient was 8.9%, the inter-assay CV was 10.1%. With an with a high CRP of 170 mg/l due to an epididymitis immunoblot, we have demonstrated that both the monoand one female OA patient with a CRP level of 44 mg/l clonal and the polyclonal antibody reacted with active who was diagnosed as having polymyalgia rheumatica MMP-3 as well as with pro-MMP-3 (data not shown).
as well. The CRP levels of the other 17 OA patients Treatment of the sera with p-aminophenyl mercury were low (median 3 mg/l, range 2-21 mg/l ). acetate (APMA) [32, 33] to activate pro-MMP-3 did
In the group of 48 RA 00/0X patients, 44 (92%) were not influence results in the ELISA. Furthermore, it was treated with DMARDs and low-dose corticosteroids demonstrated that RFs do not react in this assay and were given as adjuvant treatment in six patients (13%). do not interfere with measurement of MMP-3.
There were no differences between the RA groups in In the group of 48 patients without initial radioage, gender, RF positivity, joint pain score, joint swelling logical damage (RA-00/0X ), serum MMP-3 levels were score and Ritchie articular index. Disease duration was also measured in the BIOTRAKB MMP-3 ELISA kit shorter in the RA-00/0X group (P < 0.01). There was a (Amersham, 's Hertogenbosch, The Netherlands) borderline significant difference in initial CRP levels according to the manufacturer's recommendations at 0, between the RA-00/0X and RA-XX groups (P = 0.05). 6, 12 and 24 months.
Other laboratory measurements
Measurement of MMP-3 In patients with RA, CRP and RF were measured In the group of 48 patients without initial radiological by rate nephelometry (Behring; normal values: damage (RA-00/0X ), the serum MMP-3 levels were CRP < 3 mg/l, RF < 12 IU/ml ) at 0, 6, 12 and 24 determined with the MMP-3 ELISA developed in our months.
own laboratory and with the BIOTRAKB MMP-3 Statistical analysis ELISA. In 192 serum samples, there was a good correlation between the two tests (r = 0.96, P < 0.01). Further Correlations were analysed using Pearson correlations serum MMP-3 measurements and calculations were and Spearman's rank correlation coefficient. Differences between groups were analysed by x2 and the Mannperformed with our own MMP-3 ELISA. Values are the median and range. RA-00: at presentation no radiological damage (= 0), after 2 yr no radiological damage. RA-0X: at presentation no radiological damage (= 0), after 2 yr radiological damage; Á1 Sharp point (= X ). RA-XX: at presentation already radiological damage; Á5 Sharp points (= X ), after 2 yr radiological damage (= X ).
aRA-00/0X vs RA-XX P < 0.01. bRA-00/0X vs RA-XX P = 0.05.
T 2. Serum levels of matrix metalloproteinase-3 (MMP-3) (ng/ml ) in rheumatoid arthritis (RA), osteoarthritis (OA) patients and healthy controls (CTRL) at study entry Values are the median and range. RA-00: at presentation no radiological damage (= 0), after 2 yr no radiological damage. RA-0X: at presentation no radiological damage (= 0), after 2 yr radiological damage; Á1 Sharp point (= X ). RA-XX: at presentation already radiological damage; Á5 Sharp points (= X ), after 2 yr radiological damage (= X ).
aCTRL male vs CTRL female P < 0.01. bRA-00/0X vs CTRL P < 0.01. cRA-XX vs CTRL P < 0.01. dRA-00/0X vs RA-XX P < 0.01.
Initial serum MMP-3 level in CTRL, OA and RA
Initial serum MMP-3 levels in RA patients in relation to X-ray damage at presentation patients Serum levels of MMP-3 at study entry are summarized Serum MMP-3 levels were lower in the RA-00/0X group in comparison with the RA-XX group (P < 0.01). in Fig. 1 and Table 2 . In CTRL, the serum MMP-3 levels were undetectable (<10.0 ng/ml ) or low. In these Initial serum MMP-3 levels in the RA-00, RA-0X and control subjects, the serum MMP-3 levels in men were RA-XX subgroups higher than those in women (P < 0.01). Sex differences were not found in the groups of OA and RA patients.
During 2 yr of follow-up, 29 of the 48 patients developed X-ray damage (Á1 Sharp point). Characteristics at No differences were found in serum MMP-3 levels between CTRL and OA patients (P = 0.19). The serum study entry of the three subgroups are summarized in Table 3 . There were no significant differences between MMP-3 levels in RA patients were higher in comparison with the CTRL (RA-00/0X vs CTRL P < 0.01 and the three groups in age, gender, joint pain score, joint swelling score and Ritchie articular index. CRP levels RA-XX vs CTRL P < 0.01).
were lower in the RA-00 group (P < 0.01). In the RA-00 group (n = 19), 53% had a positive RF test, in contrast to 83% in the RA-0X group (n = 29) and 80% in the RA-XX group (n = 30) (P = 0.05).
In the RA-00 group, the serum MMP-3 levels at study the three groups of rheumatoid arthritis patients. The horiat presentation no radiological damage (= 0), after 2 yr radiological zontal line is the median. RA-00: at presentation no radiodamage; Á1 Sharp point (= X ). RA-XX: at presentation already logical damage (= 0), after 2 yr no radiological damage radiological damage; Á5 Sharp points (= X ), after 2 yr radiological (= 0). RA-0X: at presentation no radiological damage (= 0), damage.
after 2 yr radiological damage; Á1 Sharp point (= X ).
aRA-00 vs RA-0X or RA-XX P < 0.01.
RA-XX: at presentation already radiological damage; Á5
bRA-00 vs RA-0X P = 0.05. cRA-00 vs RA-XX P < 0.01.
Sharp points (= X ), after 2 yr radiological damage.
entry were lower than in the RA-XX group (P < 0.01). aggressive destructive disease is important for prognostic and therapeutic reasons. Novel more aggressive therapThe difference in serum MMP-3 levels at study entry between RA-00 and RA-0X patients reached borderline ies, including MMP inhibitors, are currently developed [34] [35] [36] [37] [38] and thus the need for clinically feasible means significance (P = 0.05). There were no significant differences in serum MMP-3 levels at study entry between for assessing the prognosis in the individual patient is becoming more and more important. the 29 patients who developed X-ray damage (RA-0X group) compared to the 30 RA-XX patients with X-ray Even though an elevated serum MMP-3 level is not unique for RA (elevated levels have also been found in damage at presentation (P = 0.11).
patients with for example systemic lupus erythematosus, Initial serum MMP-3 levels in relation to development mixed connective tissue disease and psoriatic arthritis of X-ray damage [39, 40] ), it could be a specific marker of joint inflammation and destruction in RA because it is almost exclusIn the complete group of 48 RA-00/0X patients, serum MMP-3 level at study entry correlated significantly with ively produced in the inflamed synovium. Recent studies showed close correlations between serum MMP-3 and the total Sharp score at 6 months (r = 0.34, P = 0.02) and 12 months (r = 0.32, P = 0.03). The correlation disease activity in RA [39, 41] . As far as we know, there are no studies reported that link serum MMP-3 to the between serum MMP-3 level at study entry and total Sharp score at 24 months reached borderline significance development of radiological damage in RA.
In the present study, we evaluated the significance of (r = 0.28, P = 0.05). Further separate analysis of joint space narrowing and erosions demonstrated a significant serum MMP-3 levels in relation to the development of radiological damage in early RA. Furthermore, we correlation between serum MMP-3 levels at study entry and joint space narrowing at 6 months (r = 0.41, investigated the relationship between serum MMP-3 and CRP. P < 0.01), 12 months (r = 0.37, P < 0.01) and 24 months (r = 0.32, P = 0.03). In the subgroup of 29 As in other studies [14, 20, 31] , we found that serum MMP-3 levels were undetectable or low in normal RA-0X patients, there was also a significant correlation between serum MMP-3 at presentation and joint space CTRL and OA patients. In healthy male CTRL, serum MMP-3 levels appeared to be higher than in healthy narrowing at 6 months (r = 0.42, P = 0.02) and 12 months (r = 0.37, P = 0.04). There were no correlations female CTRL, a phenomenon which has been reported before [14, 40] . Sex differences were not found in OA between initial serum MMP-3 levels and erosions at any time point.
patients (possibly due to the skewed distribution) nor in RA patients (possibly due to the fact that small sex At a cut-off point for serum MMP-3 of 80 ng/ml (the upper limit of CTRL and OA patients), we found a differences were overruled by the massive production of MMP-3 in these patients). Further analysis of serum positive predictive value for the development of X-ray damage within 2 yr of 91.7% (sensitivity 37.9%, specifi-MMP-3 levels in normal controls with respect to gender, age and variation in time is of interest because these city 94.7%).
variables could be important in determining the cut-off Serum MMP-3 levels in relation to clinical parameters point between normal and abnormal values (study in and CRP in the 48 patients without initial X-ray progress). damage Serum MMP-3 levels in RA patients were higher than in CTRL. Initial MMP-3 levels in patients with X-ray Serum MMP-3 correlated with joint swelling at study entry and after 24 months. The other clinical parameters damage at presentation (RA-XX ) were higher than the levels in patients without any X-ray damage during did not correlate with MMP-3 at any time point.
Serum MMP-3 levels correlated with CRP at study follow-up ( RA-00), but were not different from those in patients who developed X-ray damage during the entry (r = 0.42, P < 0.01), 6 months (r = 0.56, P < 0.01), 12 months (r = 0.52, P < 0.01) and 24 study (RA-0X ). In other words, a high initial serum MMP-3 level was associated with the development of months (r = 0.38, P < 0.01).
A logistic regression model, with X-ray damage at 6, radiological damage (positive predictive value for the development of X-ray damage within 2 yr of 91.7%, at 12, 24 months as dependent variable and MMP-3 level and/or CRP level at study entry as independent varia cut-off point for serum MMP-3 of 80 ng/ml ). In the group of 48 patients without initial X-ray ables, reached significance for CRP levels at study entry and X-ray damage at 6 and 24 months. In the combined damage (RA-00/0X ), we found a significant correlation between initial serum MMP-3 levels and the developmodel of MMP-3 and CRP, MMP-3 had no additive predictive value for the explained variance of X-ray ment of X-ray damage which was mainly determined by joint space narrowing in the Sharp score. In the subdamage at these time points. Separate analysis of joint space narrowing and erosions did not influence these group of 29 patients who developed X-ray damage during follow-up (RA-0X ), there was also a significant results.
correlation between initial serum MMP-3 levels and joint space narrowing in the Sharp score. The finding Discussion that initial serum MMP-3 levels correlate with joint space narrowing fits with the fact that the main targets Research on MMPs in an early phase of RA is of interest because early identification of patients with of MMP-3 are localized in the matrix of cartilage, like proteoglycans [1, [9] [10] [11] , and the fact that in animal
